Literature DB >> 2511447

Plasma viremia in human immunodeficiency virus infection.

R W Coombs1, A C Collier, J P Allain, B Nikora, M Leuther, G F Gjerset, L Corey.   

Abstract

To determine which markers of human immunodeficiency virus type 1 (HIV) replication correlate most closely with progressive disease, we compared the following: (1) the frequency of isolation of HIV from peripheral-blood mononuclear cells (PBMC), (2) the frequency of isolation of the virus from cell-free plasma (plasma viremia), (3) the presence and titer of p24 antigen in plasma, and (4) the presence and titer of antibody to p24 antigen. We studied 213 persons who were positive for HIV antibody and 71 who were negative. HIV was isolated from PBMC from 207 of the 213 antibody-positive patients (97 percent), regardless of the clinical stage of the infection. Plasma viremia, in contrast, was correlated with the clinical stage of the infection. It was detected in 11 of 48 patients (23 percent) with asymptomatic infection, 32 of 71 (45 percent) in Class IVa of the Centers for Disease Control (those with AIDS-related complex), and 75 of 92 (82 percent) in Class IVc (those with AIDS) (P less than 0.01). Plasma HIV titers ranged from 10(0) to 10(4.3) and rose from a mean of 10(1.4) in asymptomatic patients to 10(2.5) in those with AIDS (P less than 0.02). Only 45 percent of patients with plasma viremia had HIV p24 antigen in either serum or plasma, and no correlation was found between the amount of p24 antigen in plasma and the plasma HIV titers. Follow-up tests indicated that plasma viremia was associated with a more marked decline in the CD4-lymphocyte cell count and the development of symptomatic disease (P = 0.034). We conclude that plasma viremia is a more sensitive virologic marker of the clinical stage of HIV infection and viral replication than the presence of p24 antigen or antibody in plasma. Not only whole blood but cell-free plasma from HIV-infected patients should be considered potentially infectious.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2511447     DOI: 10.1056/NEJM198912143212402

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  129 in total

1.  Virus load and sequence variation in simian retrovirus type 2 infection.

Authors:  L L Rosenblum; R A Weiss; M O McClure
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Comparison of the frequencies and levels of human immunodeficiency virus type 1 markers in specimens from chronically infected human T-lymphocyte cultures and from patients.

Authors:  D J Witt; C C Ginocchio; X P Wang; M K Kaufman
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Dangers of neonatal intubation with the Cole tube.

Authors:  M D Mitchell; C M Bailey
Journal:  BMJ       Date:  1990-09-22

4.  Spontaneous release of interferon as a predictor of clinical evolution in HIV-positive subjects.

Authors:  A Biglino; A Surbone; F Lipani; N Cappello; B Forno; A M Pollono; M Busso; A Pugliese
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

5.  Whole body positron emission tomography imaging of simian immunodeficiency virus-infected rhesus macaques.

Authors:  A M Scharko; S B Perlman; J M Hanson; H Uno; C D Pauza
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

6.  A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.

Authors:  D Weissman; G Poli; A Bousseau; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

7.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

Review 8.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

9.  Real-time PCR assay of individual human immunodeficiency virus type 1 variants in coinfected human lymphoid tissues.

Authors:  Yoshinori Ito; Jean-Charles Grivel; Leonid Margolis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 10.  Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop.

Authors:  D D Richman; D Havlir
Journal:  Drugs       Date:  1995       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.